| 0.9064 -0.434 (-32.36%) | 12-15 15:59 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 1.4 |
1-year : | 1.68 |
| Resists | First : | 1.2 |
Second : | 1.44 |
| Pivot price | 1.1 |
|||
| Supports | First : | 0.82 |
Second : | 0.68 |
| MAs | MA(5) : | 1.15 |
MA(20) : | 1.09 |
| MA(100) : | 1 |
MA(250) : | 0 | |
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 62.5 |
D(3) : | 75.9 |
| RSI | RSI(14): 40.1 |
|||
| 52-week | High : | 2.43 | Low : | 0.77 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ LEXX ] has closed below the lower bollinger band by 3.8%. Although price has broken the lower band and a downside breakout is possible; the most likely direction for [ LEXX ] is to continue within current trading range. Bollinger Bands are 12.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 1 - 1.01 | 1.01 - 1.01 |
| Low: | 0.81 - 0.82 | 0.82 - 0.82 |
| Close: | 0.9 - 0.91 | 0.91 - 0.91 |
Lexaria Bioscience Corp. operates as a biotechnology company. Its patented drug delivery technology, DehydraTECH, improves the way active pharmaceutical ingredients enter the bloodstream by promoting effective oral delivery. The company's DehydraTECH has demonstrated the ability to increase bio-absorption with cannabinoids and nicotine by 5-10x and in some instances with cannabinoids by 27x compared to standard industry formulations, reduce time of onset from 1 - 2 hours to minutes, and mask unwanted tastes; and is also being evaluated for orally administered anti-viral drugs, non-steroidal anti-inflammatory drugs (NSAIDs), PDE5 inhibitors, and others. DehydraTECH also deliver drugs effectively across the blood brain barrier. It operates a licensed in-house research laboratory and holds intellectual property portfolio with 23 patents granted and approximately 50 patents pending worldwide. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
Mon, 15 Dec 2025
LEXX Appoints H.C. Wainwright & Co. as Exclusive Placement Agent - GuruFocus
Mon, 15 Dec 2025
Lexaria Bioscience stock plunges after $3.5M at-the-market offering - Investing.com
Mon, 15 Dec 2025
Lexaria (NASDAQ: LEXX) prices $3.5M direct stock offering, adds 5-year warrants - Stock Titan
Sat, 29 Nov 2025
Lexaria Bioscience Corp. (NASDAQ:LEXX): Are Analysts Optimistic? - Yahoo Finance
Wed, 12 Nov 2025
Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended - Investing News Network
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 22 (M) |
| Held by Insiders | 2.079e+007 (%) |
| Held by Institutions | 6.8 (%) |
| Shares Short | 741 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -1.155e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -1 % |
| Return on Assets (ttm) | 422.2 % |
| Return on Equity (ttm) | -111.5 % |
| Qtrly Rev. Growth | 705920 % |
| Gross Profit (p.s.) | 172.74 |
| Sales Per Share | -374.44 |
| EBITDA (p.s.) | 1.13419e+006 |
| Qtrly Earnings Growth | -0.7 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 3.74 |
| Dividend | 0 |
| Forward Dividend | 605050 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|